The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the hepatic encephalopathy market in recent years?
The growing prevalence of liver diseases is expected to propel the growth of the hepatic encephalopathy market going forward. Liver disease is a medical condition affecting the liver and impairing its function. Liver disease treatments such as hepatic encephalopathy can alleviate symptoms, slow disease progression, improve liver function and reduce hepatic encephalopathy occurrences by improving the management of underlying conditions, potentially reducing frequency and severity and enhancing patients’ overall quality of life. For instance, in April 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, hospital admission rates for liver disease have continued to increase, reaching 155.2 per 100,000 population (with a range of 152.9 to 157.5) in the financial year ending 2023, up from 150.6 (148.2 to 152.9) the previous year. Therefore, the growing prevalence of liver diseases drives the hepatic encephalopathy market.
Hepatic Encephalopathy Market Driver: Rising Healthcare Expenditures Expected To Propel Hepatic Encephalopathy Market Growth
Increasing healthcare expenditures are anticipated to propel the growth of the hepatic encephalopathy market. Healthcare expenditures refer to the total amount spent on healthcare-related services, products, and activities within a specified period, typically on an individual, community, national, or global level. Higher healthcare expenditures can positively impact hepatic encephalopathy treatment options by facilitating advancements in diagnosis, treatment, awareness, and patient care. For instance, in December 2023, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, U.S. health care spending rose by 4.1% in 2022, reaching $4.5 trillion, a higher growth rate than the 3.2% increase seen in 2021. Therefore, increasing healthcare expenditure will drive the growth of the hepatic encephalopathy market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12906&type=smp
What is the projected market size of the hepatic encephalopathy industry, and how is it expected to grow?
The hepatic encephalopathy market size has grown strongly in recent years. It will grow from $1.72 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to prevalence of liver diseases, growing awareness about hepatic encephalopathy, government initiatives, increasing new liver therapies.
The hepatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing ageing population, surge in treatment options, rising expenditure on healthcare infrastructure, investments on hepatic encephalopathy treatments. Major trends in the forecast period include launch of emerging therapies, research and clinical trials, advances in liver transplantation, pharmaceutical innovations, advances in nutrition and dietary management, adption of telemedicine and remote monitoring.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12906&type=smp
Who are the key players driving competition in the hepatic encephalopathy market?
Major companies operating in the hepatic encephalopathy market are Umecrine Cognition AB, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Lupin Limited, Salix Pharmaceuticals, Norgine B.V., Ferring B.V., ASKA Pharmaceutical Co. Ltd., Vedanta Biosciences Inc., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Ochsner Health Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Mallinckrodt PLC, Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., ASKA Pharmaceutical Co. Ltd., Norgine B.V.
What key trends are expected to drive the hemp rebar market during the forecast period?
Major companies operating in the hepatic encephalopathy market are developing innovative drugs to treat hepatic encephalopathy to gain competitive advantages and strengthen their position in the market. For instance, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, developed the novel GR3027 (golexanolone) to treat hepatic encephalopathy. This is an orally administered small molecule and a GABAA-receptor-modulating steroid antagonist (GAMSA) designed to antagonize positive GABAA-receptor modulation by endogenous neuroactive steroids. Additionally, the drug is being investigated for HE. The trial is being conducted for CHE in Phases I/IIa.
Which key geographies are driving the growth of the hepatic encephalopathy market?
North America was the largest region in the hepatic encephalopathy market in 2024. The regions covered in hepatic encephalopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report
What are the key segments driving growth in the hepatic encephalopathy market?
The hepatic encephalopathy market covered in this report is segmented –
1) By Drug Class: Antibiotics, Laxatives, L-Ornithine, L-Aspartate, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous, Rectal
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antibiotics: Rifaximin, Neomycin, Metronidazole
2) By Laxatives: Lactulose, Polyethylene Glycol, Sorbitol
3) By L-Ornithine, L-Aspartate: L-Ornithine L-Aspartate
4) By Other Drug Classes: Zinc Supplements, Probiotics, Hepatoprotective Agents
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12906
How is the hepatic encephalopathy market defined, and what are its core characteristics?
Hepatic encephalopathy is a condition characterized by a decline in brain function resulting from severe liver disease. It is a reversible syndrome of impaired brain function in patients with advanced liver diseases. Treating hepatic encephalopathy (HE) involves managing the underlying liver disease, reducing ammonia levels in the blood and addressing neurological symptoms.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
